Azenta stock
AZTANASDAQAzenta, Inc., HealthcareISIN US1143401024
50Score 50 out of 100, Neutral
Price and trend
88 / 100
Price history
+43% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 55% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 10% below its 52-week high. Largest decline in 20 years: 87% (November 2021 to May 2026).
Chart figures for advanced users
- SMA 50$36.23
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$28.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.02
- The lowest closing price of the last twelve months.
- Resistance$48.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Azenta, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $1.92B, is number 33 of 44 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $621.7M (up 4.7% year on year) and a loss of $166.99M.
- For fiscal 2027, analysts expect on average revenue of $651.4M (up 4.8%) and adjusted earnings per share of $0.56 (up 13.3%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 372 of 702 in Healthcare, median 53.
- Our model puts fair value at $19.74, with the price 122% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 39% since 2021.Capital allocation 55
- Analysts expect strong earnings growthUp 32.5% a year through 2028 (estimates from 3 analysts).
- More cash than debtCash $332.68M, financial debt $51.87M.Stability 71
Weaknesses
- Above fair valuePrice 122% above the fair value of $19.74.Valuation 27
- Loss-makingLoss of $166.99M over the last 12 months.Fundamentals 31
- Volatile share priceVolatility 69% a year over the last 12 months.
Its standout strengths are momentum and technical analysis, while valuation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 52 to 50.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $13.16 and expensive above $39.47 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $16.21, at 7.8% it would be $25.05.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 4.7% on the prior year. Revenue has stayed largely stable since 2007.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 44%, operating −28%, net −27%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 10 Nov 2026EPS reported $0.28 (expected $0.11)above expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 19.0% since 15 Oct 2026.
- Earnings per share
- $0.56+6.2%
- Revenue
- $651.4M+1.9%
- Earnings per share
- $0.86+19.0%
- Revenue
- $687.23M+2.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.0%Outlook raised: organic revenue flat to up 1% (previously down 2% to up 1%), revenue of $613 million to $618 million, adjusted EBITDA of $59 million to $62 million.
“We now expect reported revenue in the range of $613 million to $618 million, improving our organic revenue outlook to approximately flat to up 1% year-over-year, with adjusted EBITDA expected to be in the range of $59 million to $62 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $171,896 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Azenta
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Carl Zeiss MeditecAFX.DE $3.34B64
- AtriCureATRC $2.85B51
- AddLifeALIF-B.ST $2.14B58
- Bonesupport HoldingBONEX.ST $2.07B72
- SKAN GroupSKAN.SW $1.87B72
- DENTSPLY SIRONAXRAY $1.84B46
- LeMaitre VascularLMAT $1.78B70
- Kestra Medical TechnologiesKMTS $1.7B43
ETFs that hold Azenta
Held by 4 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.31B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.10% | €395.74M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.5B |
Show 1 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Weak
- Valuation signal Overvalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.